[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmziSMNpAsag9DanKmu1MaFt7Z2oSsRJxyZYHkgnGZ7U":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Virginia Polytechnic Institute and State University",[4],121,false,31,1,16561,0,111,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Cigarette Smoking",10,{"name":18,"count":19},"Prediabetes",5,{"name":21,"count":19},"Alcohol Use Disorder",{"name":23,"count":24},"Chronic Pain",4,{"name":26,"count":24},"Obesity",{"name":28,"count":24},"Cigarette Smoking Behavior",{"name":30,"count":24},"Cardiovascular Risk Factor",{"name":32,"count":24},"Overweight and Obesity",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,71,95,120,146,164,189,207,234,252,278,296,321,349,367,385,403],{"intervention":43,"totalTrials":9,"cells":44},"Olmesartan medoxomil",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":69},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":68},"NCT01684748","Angiotensin II Blockade and Inflammation in Obesity","COMPLETED",[39],"2011-08","2009-02",20,[64,65,66,67],"Overweight","Obese","Prehypertension","Hypertension",[43],{"trials":70,"activeCount":11},[],{"intervention":72,"totalTrials":9,"cells":73},"Nebivolol",{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":93},{"trials":75,"activeCount":11},[],{"trials":77,"activeCount":11},[],{"trials":79,"activeCount":11},[],{"trials":81,"activeCount":11},[],{"trials":83,"activeCount":11},[84],{"nctId":85,"briefTitle":86,"status":58,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":92},"NCT01920282","Nebivolol, Lifestyle Modification and Arterial Stiffness",[39],"2012-08","2010-01",45,[67],[72],{"trials":94,"activeCount":11},[],{"intervention":96,"totalTrials":9,"cells":97},"Triamcinolone Acetonide 40mg\u002FmL",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":118},{"trials":99,"activeCount":11},[],{"trials":101,"activeCount":11},[],{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[108],{"nctId":109,"briefTitle":110,"status":58,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT04701593","Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery",[39],"2022-10-20","2020-01-03",14,[116],"Retinal Detachment",[96],{"trials":119,"activeCount":11},[],{"intervention":121,"totalTrials":9,"cells":122},"Intranasal Insulin",{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[127],{"nctId":128,"briefTitle":129,"status":58,"phases":130,"primaryCompletion":131,"completion":132,"start":133,"enrollment":90,"conditions":134,"interventions":136},"NCT02758691","fMRI Study of Effects of Nasal Insulin on Memory",[36],"2016-06","2017-05-10","2015-12",[135,121],"Human Memory",[121,137],"Intranasal Saline",{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[],{"intervention":137,"totalTrials":9,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":162},{"trials":149,"activeCount":11},[],{"trials":151,"activeCount":11},[152],{"nctId":128,"briefTitle":129,"status":58,"phases":153,"primaryCompletion":131,"completion":132,"start":133,"enrollment":90,"conditions":154,"interventions":155},[36],[135,121],[121,137],{"trials":157,"activeCount":11},[],{"trials":159,"activeCount":11},[],{"trials":161,"activeCount":11},[],{"trials":163,"activeCount":11},[],{"intervention":165,"totalTrials":9,"cells":166},"Reat ETM",{"EARLY_PHASE1":167,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":187},{"trials":168,"activeCount":11},[169],{"nctId":170,"briefTitle":171,"status":58,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":177},"NCT05946031","Testing the ETM: Examination and Comparison of Different Methods",[35],"2025-08-14","2024-07-28",87,[15],[165,178],"Hypothetical ETM",{"trials":180,"activeCount":11},[],{"trials":182,"activeCount":11},[],{"trials":184,"activeCount":11},[],{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[],{"intervention":178,"totalTrials":9,"cells":190},{"EARLY_PHASE1":191,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":192,"activeCount":11},[193],{"nctId":170,"briefTitle":171,"status":58,"phases":194,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":195,"interventions":196},[35],[15],[165,178],{"trials":198,"activeCount":11},[],{"trials":200,"activeCount":11},[],{"trials":202,"activeCount":11},[],{"trials":204,"activeCount":11},[],{"trials":206,"activeCount":11},[],{"intervention":208,"totalTrials":9,"cells":209},"Vitamin D 10000 UNT",{"EARLY_PHASE1":210,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":211,"activeCount":11},[212],{"nctId":213,"briefTitle":214,"status":58,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT03151174","Effects of Vitamin D Supplementation on Strength, Bone Density, and Injury Risk in Collegiate Athletes",[35],"2018-05-15","2018-06-01","2017-04-29",68,[221],"Vitamin D Deficiency",[208,223],"Vitamin D 5000 UNT",{"trials":225,"activeCount":11},[],{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[],{"trials":231,"activeCount":11},[],{"trials":233,"activeCount":11},[],{"intervention":223,"totalTrials":9,"cells":235},{"EARLY_PHASE1":236,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":237,"activeCount":11},[238],{"nctId":213,"briefTitle":214,"status":58,"phases":239,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":240,"interventions":241},[35],[221],[208,223],{"trials":243,"activeCount":11},[],{"trials":245,"activeCount":11},[],{"trials":247,"activeCount":11},[],{"trials":249,"activeCount":11},[],{"trials":251,"activeCount":11},[],{"intervention":253,"totalTrials":9,"cells":254},"SPECTRUM cigarettes",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":265},{"trials":256,"activeCount":11},[],{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[],{"trials":264,"activeCount":11},[],{"trials":266,"activeCount":11},[267],{"nctId":268,"briefTitle":269,"status":58,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT02951143","Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace",[40],"2019-11","2017-01",305,[275],"Substance-Related Disorders",[253,277],"SPECTRUM cigarettes between",{"intervention":277,"totalTrials":9,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":290},{"trials":281,"activeCount":11},[],{"trials":283,"activeCount":11},[],{"trials":285,"activeCount":11},[],{"trials":287,"activeCount":11},[],{"trials":289,"activeCount":11},[],{"trials":291,"activeCount":11},[292],{"nctId":268,"briefTitle":269,"status":58,"phases":293,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":294,"interventions":295},[40],[275],[253,277],{"intervention":297,"totalTrials":9,"cells":298},"Suboxone",{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":300,"activeCount":11},[],{"trials":302,"activeCount":11},[],{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[],{"trials":308,"activeCount":11},[],{"trials":310,"activeCount":11},[311],{"nctId":312,"briefTitle":313,"status":58,"phases":314,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":320},"NCT00929253","Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)",[40],"2010-04","2007-09",170,[319],"Opiate Addiction",[297],{"intervention":322,"totalTrials":9,"cells":323},"3 mg\u002FmL nicotine strength e-liquid",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":11},[],{"trials":327,"activeCount":11},[],{"trials":329,"activeCount":11},[],{"trials":331,"activeCount":11},[],{"trials":333,"activeCount":11},[],{"trials":335,"activeCount":11},[336],{"nctId":337,"briefTitle":338,"status":58,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT03843047","Electronic Cigarette Unit Price Manipulations in the Experimental Tobacco Marketplace",[40],"2021-09-30","2019-03-01",81,[344],"Tobacco Use",[322,346,347,348],"6 mg\u002FmL nicotine strength e-liquid","12 mg\u002FmL nicotine strength e-liquid","24 mg\u002FmL nicotine strength e-liquid",{"intervention":346,"totalTrials":9,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":352,"activeCount":11},[],{"trials":354,"activeCount":11},[],{"trials":356,"activeCount":11},[],{"trials":358,"activeCount":11},[],{"trials":360,"activeCount":11},[],{"trials":362,"activeCount":11},[363],{"nctId":337,"briefTitle":338,"status":58,"phases":364,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":365,"interventions":366},[40],[344],[322,346,347,348],{"intervention":347,"totalTrials":9,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":370,"activeCount":11},[],{"trials":372,"activeCount":11},[],{"trials":374,"activeCount":11},[],{"trials":376,"activeCount":11},[],{"trials":378,"activeCount":11},[],{"trials":380,"activeCount":11},[381],{"nctId":337,"briefTitle":338,"status":58,"phases":382,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":383,"interventions":384},[40],[344],[322,346,347,348],{"intervention":348,"totalTrials":9,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":388,"activeCount":11},[],{"trials":390,"activeCount":11},[],{"trials":392,"activeCount":11},[],{"trials":394,"activeCount":11},[],{"trials":396,"activeCount":11},[],{"trials":398,"activeCount":11},[399],{"nctId":337,"briefTitle":338,"status":58,"phases":400,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":401,"interventions":402},[40],[344],[322,346,347,348],{"intervention":404,"totalTrials":9,"cells":405},"Loteprednol Etabonate Ophthalmic Gel [Lotemax]",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":407,"activeCount":11},[],{"trials":409,"activeCount":11},[],{"trials":411,"activeCount":11},[],{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"trials":417,"activeCount":11},[418],{"nctId":419,"briefTitle":420,"status":58,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":428},"NCT05542381","The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain",[40],"2024-05-01","2025-05-01","2022-12-22",64,[427],"Age-Related Macular Degeneration",[404]]